期刊文献+

肺动脉球囊扩张成形术治疗慢性血栓栓塞性肺动脉高压的疗效观察 被引量:6

A retrospective study of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
原文传递
导出
摘要 目的分析肺动脉球囊扩张成形术(BPA)治疗慢性血栓栓塞性肺动脉高压(CTEPH)的有效性及安全性。方法回顾性纳入2017年2月至2019年4月在北京朝阳医院进行过至少1次BPA治疗并行肺动脉压力测定,已充分抗凝治疗3个月,不能手术的CTEPH患者38例,其中男12例,女26例,中位年龄58.5(52.5,66.0)岁。采集患者基线资料及每次BPA前的WHO功能分级、6 min步行距离、平均肺动脉压(mPAP)、肺血管阻力(PVR)、N末端B型利钠肽原(NT-proBNP)及超声心动图等指标。结果38例患者共进行95次BPA治疗。行BPA前mPAP为50(43,56)mmHg(1 mmHg=0.133 kPa),行至少1次BPA后mPAP为41(32,50)mmHg(P<0.001)。17例患者完成3~5次BPA,mPAP由50(42,55)降至34(28,49)mmHg(P<0.01)。15例患者的PVR从852(583,1140)dyn·s·cm^-5降至496(406,802)dyn·s·cm^-5(P<0.01)。BPA前WHO功能分级Ⅰ/Ⅱ级患者13例,Ⅲ/Ⅳ级患者25例,BPA治疗后WHO功能分级Ⅰ/Ⅱ级患者29例,Ⅲ/Ⅳ级患者9例(P<0.001)。BPA后6 min步行距离从360(290,442)m增加至449(376,505)m(P<0.05)。肺灌注Meyer评分从0.54(0.53,0.58)降至0.50(0.44,0.58,P<0.001)。21例患者的NT-proBNP从1285(606,2794)ng/L降至472(148,745)ng/L(P<0.05)。右心室基底内径由术前的54(41,54)mm降至42(34,49)mm(P<0.001)。6例次发生不良反应,发生率为6.3%(6/95)。结论对于不能行肺动脉血栓内膜剥脱术的CTEPH患者,BPA可有效降低肺动脉压力及肺血管阻力,改善肺灌注及右心功能,且安全性高,是CTEPH较为有效的治疗方法。 Objective To analyze the efficacy and safety of Balloon Pulmonary Angioplasty(BPA)in patients with Chronic Thromboembolic Pulmonary Hypertension(CTEPH).Methods A total of 38 CTEPH patients received at least one BPA treatment between February 2017 and April 2019 were enrolled.World Health Organization functional class(WHO-FC),6-minute walking distance(6WMD),mean pulmonary artery pressure(mPAP),pulmonary vascular resistance(PVR),N-terminal pro brain natriuretic peptide(NT-proBNP)and echocardiographic indicators were collected at baseline and before each BPA procedure.Results 38 patients received 95 times of BPA[2(1,4)times per person]totally.MPAP was 50(43,56)mmHg(1 mmHg=0.133 kPa)before BPA and 41(32,50)mmHg after at least one BPA procedure,P<0.001.MPAP decreased from 50(42,55)to 34(28,49)mmHg(P=0.003)in 17 cases after 3-5 BPA procedures.In 15 cases,PVR decreased from 852(583,1140)dyn·s·cm^-5 to 496(406,802)dyn·s·cm^-5,P=0.009.Besides,there were 13 patients with WHO Function ClassⅠ/Ⅱbefore BPA,25 patients withⅢ/Ⅳclass before BPA,29 patients withⅠ/Ⅱclass after BPA treatment,and 9 patients withⅢ/Ⅳafter BPA treatment,P<0.001.6 WMD before and after BPA increased from 360(290,442)m to 449(376,505)m,P=0.015.The Meyer score of lung perfusion scanning got improved,from 0.54(0.53,0.58)to 0.50(0.44,0.58),P<0.001.Among all registered patients,21 of whom NT-proBNP decreased from 1285(606,2794)to 472(148,745),P=0.014.The inner diameter of the right ventricular decreased from 54(41,54)mm before surgery to 42(34,49)mm after surgery,P<0.001.6(6.3%,6/95)complications occurred in 95 times of BPA.Conclusion For inoperable patients with CTEPH,BPA can significantly improve disease severity,6 MWD,heart function,decrease mPAP,PVR and improve lung perfusion,which is a safe and effective therapy.
作者 丁媛 龚娟妮 王剑锋 黄强 刘琳 焦小净 汪薇 杨媛华 Ding Yuan;Gong Juanni;Wang Jianfeng;Huang Qiang;Liu Lin;Jiao Xiaojing;Wang Wei;Yang Yuanhua(Department of Respiratory and Critical Care Medicine,Beijing Chaoyang Hospital,Capital Medical University,Beijing Institute of Respiratory Medicine,Beijing 100020,China;Department of Interventional Medicine,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China)
出处 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2020年第12期1049-1054,共6页 Chinese Journal of Tuberculosis and Respiratory Diseases
基金 国家自然科学基金(31670928)。
关键词 肺动脉球囊扩张成形术 慢性血栓栓塞性肺动脉高压 治疗 Balloon pulmonary angioplasty Chronic thromboembolic pulmonary hypertension Treatment
  • 引文网络
  • 相关文献

参考文献2

二级参考文献42

  • 1杨媛华,王铁,许晓岩,王辰.异常灌注评分法评价肺血栓栓塞症患者治疗效果的价值[J].中华核医学杂志,2006,26(6):346-348. 被引量:4
  • 2Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronicthromboembolic pulmonary hypertension after a first episode ofpulmonary embolism. Chest, 2006,130:172-175. 被引量:1
  • 3Pengo V, Lensing AW, Prins MH, et al. Incidence of chronicthromboembolic pulmonary hypertension after pulmonaryembolism. N Engl J Med, 2004,350:2257-2264. 被引量:1
  • 4Poll D,Grifoni E,Antonucci E,et al. Incidence of recurrentvenous thromboembolism and of chronic thromboembolic pulmonaryhypertension in patients after a first episode of pulmonaryembolism. J Thromb Thrombolysis, 2010,30:294-299. 被引量:1
  • 5Riedel M, Stanek V,Widimsky J,et al. Longterm follow-up ofpatients with pulmonary thromboembolism. Late prognosis andevolution of hemodynamic and respiratory data Chest, 1982 ,81 :151-158. 被引量:1
  • 6Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes inmedically and surgically treated chronic thromboembolic pulmonaryhypertension. Am J Respir Crit Care Med,2008,177 :1122-1127. 被引量:1
  • 7Kirson NY, Bimbaum HG, Ivanova JI, et al. Prevalence ofpulmonary arterial hypertension and chronic thromboembolicpulmonary hypertension in the United States. Curr Med Res Opin,2011,27:1763-1768. 被引量:1
  • 8Escribano-Subias P, Blanco I,L6pez-Meseguer M,et al. Survivalin pulmonary hypertension in spain insights from the spanishregistry. Eur Respir J,2012:23. 被引量:1
  • 9Kunieda T, Nakanishi N, Satoh T, et al. Prognoses of primarypulmonary hypertension and chronic majorvessel thromboembolicpulmonary hypertension determined from cumulative survivalcurves. Intern Med, 1999,38:543-546. 被引量:1
  • 10Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors inmedically treated patients with chronic pulmonary embolism.Chest, 2001,119:818-823. 被引量:1

共引文献11

同被引文献38

引证文献6

二级引证文献3

;
使用帮助 返回顶部